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The Current and Future Treatment 
of Brain Metastases
Douglas A. Hardesty and Peter Nakaji*
Department of Neurosurgery, Barrow Neurological Institute, St. Joseph’s Hospital and Medical Center, Phoenix, AZ, USA
Brain metastases are the most common intracranial malignancy, accounting for sig-
nificant morbidity and mortality in oncology patients. The current treatment paradigm 
for brain metastasis depends on the patient’s overall health status, the primary tumor 
pathology, and the number and location of brain lesions. Herein, we review the modern 
management options for these tumors, including surgical resection, radiotherapy, and 
chemotherapy. Recent operative advances, such as fluorescence, confocal microscopy, 
and brachytherapy, are highlighted. With an increased understanding of the pathophys-
iology of brain metastasis come increased future therapeutic options. Therapy targeted 
to specific tumor molecular pathways, such as those involved in blood–brain barrier
transgression, cell–cell adhesion, and angiogenesis, are also reviewed. A personalized 
plan for each patient, based on molecular characterizations of the tumor that are used to 
better target radiotherapy and chemotherapy, is undoubtedly the future of brain metas-
tasis treatment.
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inTRODUCTiOn
Nearly 200,000 patients are newly diagnosed with brain metastases annually in the United States, 
and metastases of the lung, skin, kidney, breast, and gastrointestinal tract are the most common 
intracranial malignancies (1, 2). Historically, overall survival after diagnosis is poor; however, in 
the last 30  years, improved systemic disease therapies and multimodality brain metastasis treat-
ment have substantially increased survival. This increase in the quantity of life after diagnosis allows 
clinicians to minimize morbidity and focus on the patient’s quality of life. Choosing an appropriate 
personalized treatment plan for patients with brain metastasis maximizes survival and minimizes 
morbidity from unnecessary or futile treatments. The wide variety of tumor types, treatment strate-
gies, and constant innovations within the field requires close collaboration among neurosurgeons, 
medical oncologists, radiation oncologists, and other specialists. Current treatment paradigms for 
brain metastases employ several treatment modalities, including open surgical resection, Gamma 
Knife or CyberKnife stereotactic radiosurgery, focused external beam radiotherapy, whole-brain 
radiotherapy (WBRT), traditional chemotherapy, and newer targeted biological agents personalized 
for tumor type. We review the current standards of care for brain metastases and summarize modern 
advances in their intraoperative diagnosis and treatment (Table 1). Lastly, we provide an overview of 
recent basic science and translational research leading to better understanding of the personalized 
biology of brain metastasis through modern genomic, transcriptomic, and proteomic techniques.
Abbreviations: 5-ALA, 5-aminolevulinic acid; CNS, central nervous system; LITT, laser interstitial thermal therapy; WBRT, 
whole-brain radiotherapy.
TABLe 1 | Modern challenges in the multimodality management of brain 
metastasis.
Challenge in brain 
metastasis management
Potential 
consequence to 
patient
Modern treatment 
solution(s)
Identification of microscopic 
brain–tumor interface at time 
of surgery
Residual 
micrometastasis 
left behind despite 
resection
Intraoperative 
fluorescence, handheld 
confocal microscopy
Inability to target tumor 
bed with external beam 
radiation due to radiosensitive 
structures, prior radiation, etc.
Out-of-field 
recurrence, 
or conversely, 
radiation toxicity
Intracavitary brachytherapy, 
improved modern 
stereotactic radiosurgery-
targeting software
Inaccessible tumor or patient 
unable/unwilling to tolerate 
open surgery
Inability to achieve 
cytoreduction and 
tissue diagnosis
Stereotactic biopsy with 
MRI-guided laser interstitial 
thermal therapy (LITT)
Negative neurocognitive 
effects of whole-brain 
radiation
Decreased patient 
quality of life
Stereotactic radiosurgery 
and other WBRT-sparing 
paradigms
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CURRenT TReATMenT PARADiGMS
Key elements driving decision-making for brain metastasis care 
are patient factors and tumor factors. Patient factors include the 
patient’s overall age, condition, and systemic disease burden, 
summarized as life expectancy independent of central nervous 
system (CNS) disease. Tumor factors include histological type, 
number, and location of lesions, and, more recently, the biology of 
the tumor based on molecular and genetic testing. Patients with 
poor life expectancy independent of CNS disease may reasonably 
be offered palliative care or no treatment for the CNS disease, 
regardless of the nature of the brain involvement. Conversely, 
patients in good medical condition with a low systemic disease 
burden, and hence a good survival chance independent of the 
brain metastases, may warrant aggressive treatment. Similarly, 
certain histological types of tumors (e.g., small cell lung cancer, 
breast cancer) are more likely to respond to adjuvant treatment 
with irradiation or chemotherapy, which can make their use ben-
eficial even for numerous or poorly located lesions. Additionally, 
the more numerous the brain metastases, the poorer the progno-
sis is, irrespective of treatment. Lesions in eloquent parts of the 
brain (i.e., those that subserve a discrete function, such as speech 
or movement) or in parts of the brain less accessible via open 
neurosurgery also connote a poorer prognosis.
Neurosurgical resection of individual symptomatic brain 
metastases remains the standard of care. Lesions causing deficits 
due to local mass effect and cerebral edema should almost always 
undergo surgical extirpation once diagnosed, particularly if the 
lesion is a new diagnosis and tissue is required for pathology. 
Modern advances in microneurosurgical techniques and intraop-
erative magnetic resonance imaging-based neuronavigation allow 
for safe resection of lesions almost anywhere in the cerebrum. For 
single metastases, Patchell et al.’s landmark randomized clinical 
trial strongly supports surgical excision (3). Patients with a single 
brain metastasis underwent surgical excision followed by radia-
tion or biopsy and radiation alone. Local control, overall survival, 
and quality of life were all significantly improved with surgical 
resection plus radiation. This study comprised mostly patients 
with lung cancer metastases who had high function status. Despite 
its lack of generalizability to all tumor patients, it remains one of 
the best randomized trials supporting neurosurgical intervention 
for brain metastases.
Traditionally, WBRT has been used after surgical resection of 
a single lesion or when there are multiple small asymptomatic 
lesions. However, WBRT carries a risk of significant cognitive 
morbidity, and WBRT-sparing strategies are increasingly used 
(4, 5). Both the American Society for Radiation Oncology and 
the National Comprehensive Cancer Network Clinical Practice 
Guidelines in Oncology have published consensus statements 
supporting stereotactic radiosurgery after surgical resection of a 
single metastasis, instead of WBRT, in patients with a single lesion 
and good systemic disease control (6, 7). This WBRT-sparing 
alternative is not supported by Level 1 randomized trial data, but 
rather by significant lesser strength evidence (8–12).
Lastly, depending on tumor histology and the organ of origin, 
standard chemotherapy is implemented at the discretion of the 
medical oncologist after the surgical site heals.
inTRAOPeRATive ADvAnCeS in 
SURGiCAL TReATMenT
neurosurgical Resection and Tumor 
visualization
Nests of tumor cells exist for several millimeters outside the 
confines of the distinct metastatic brain lesion and its gliotic 
capsule (13). Aggressive resection of this microscopic margin, 
when feasible, can reduce the local recurrence of brain metastases 
(14). Therefore, the intraoperative ability to visualize and resect 
these microscopic margins using fluorescence-guided surgery 
is of considerable interest. Fluorescence-guided neurosurgery 
has become commonplace in glioma surgery; various agents 
exploit either a degraded blood–brain barrier (e.g., fluorescein) 
or unique metabolism [e.g., 5-aminolevulinic acid (5-ALA)], 
with the goal of improving the extent of resection in infiltrative 
processes (15–19). Within vascular neurosurgery, indocyanine 
green video angiography is used in cerebral aneurysm, arterio-
venous malformation, and dural arteriovenous fistula surgery as 
an alternative or adjuvant to traditional angiography (20–24). 
Multiple authors have described intraoperative fluorescence for 
resection of metastatic tumors, albeit with less robust support 
than in glioma surgery or neurovascular surgery. Schebesch and 
colleagues published results from a series of 30 patients with 
brain metastases who underwent fluorescein-guided resection 
using a Zeiss microscope filter system (25). Most tumors (90%) 
avidly expressed fluorescein, and no patients suffered complica-
tions attributable to the intravenous dye. No control group was 
reported, but the gross-total resection rate of 83% and permanent 
neurological complication rate of 6.7% are similar to reported 
surgical results (3, 25). Therefore, the use of fluorescein requires 
additional study before definitive recommendations can be made 
about its efficacy in improving the safe extent of resection. Some 
authors have noted that the area of intraoperative fluorescence 
seems to extend well beyond the gross tumor margins, possibly 
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because of breakdown of the blood–brain barrier induced by the 
tumor. A prospective trial planned by Schebesch and colleagues 
will validate the usefulness of fluorescein in this setting. An 
alternative fluorescent agent is 5-ALA, which has found signifi-
cant use in glioma surgery. Kamp et al. reported results from a 
retrospective series of 52 patients undergoing brain metastasis 
surgery using 5-ALA (26). As with fluorescein, most tumors 
(62%) expressed 5-ALA positivity. Residual cavity fluorescence 
was detected in most patients (75%) after gross-total resection 
of the distinct metastasis. Unfortunately, only one-third of those 
patients with available histological tissue samples were found to 
harbor microscopic disease at these 5-ALA-positive margins. 
Therefore, in non-eloquent areas, the use of 5-ALA seems to drive 
“supra-maximal” resection of surrounding reactive tissue, which 
means that caution is required in eloquent areas because 5-ALA 
positivity was not particularly sensitive for residual micrometas-
tasis. These studies and others demonstrate the pressing need for 
additional research into novel fluorescent compounds to better 
define microscopic tumor margins in brain metastases.
intraoperative Diagnosis
Preoperative diagnosis of a metastatic brain tumor is not always 
obvious, especially in patients with no known primary malig-
nancy and an isolated lesion. Rapid intraoperative diagnosis via 
confocal microscopy is now a viable alternative to traditional fro-
zen sectioning with light microscopy. Given the relatively limited 
literature surrounding fluorescence to date, the in vivo application 
of intraoperative confocal microscopy is particularly appealing for 
inspection of the microscopic edges of metastatic lesions within 
the resection cavity itself. Our group has had success with the use 
of in vivo, real-time, handheld confocal microscopy for diagnosis 
of various brain tumor types and visualization of the brain–tumor 
interface (27–30). Further technological refinement is required 
for handheld confocal microscopy to be widely adopted, but it 
remains an appealing method to detect residual tumor.
Brachytherapy
Radioactive brachytherapy seeds used in neurosurgery have had 
mixed results for a half-century (31–33). Brachytherapy enables 
delivery of high doses of radiation with quick dose fall-off and 
custom dosing to areas of residual tumor while sparing nearby 
radiosensitive structures via selective seed placement within the 
resection cavity. Isotypes used for intracranial brachytherapy 
have evolved significantly since the 1960s, with cesium-131 and 
iodine-125 now replacing older gold- and iridium-based therapies. 
Modern intracranial brachytherapy has been studied in atypical 
and anaplastic meningiomas, low- and high-grade gliomas, and 
metastases (34, 35). Most recently, the use of cesium-131 in brain 
metastases was reported by Wernicke et  al. from a Phase I/II 
trial (36). Twenty-four patients underwent first-time gross-total 
resection of a brain metastasis and intraoperative placement of a 
permanent cesium-131 source with a planned dose of 80 Gy to a 
surface depth of 5 mm beyond the resection cavity. The patients 
had no local recurrences, no incidents of symptomatic radiation 
necrosis, and minimal surgical morbidity. This study was limited 
by its small size, limited follow-up, and the confounding variable 
of gross-total resection, which is associated with lower rates of 
recurrence and progression. Future studies will likely confirm 
these promising preliminary results with cesium-based brachy-
therapy for treatment of brain metastases.
Laser interstitial Thermal Therapy
The use of MR-guided laser interstitial thermal therapy (LITT) 
for metastasis has been reported in the neurosurgical literature. 
MR-guided thermal ablation is not a new technology, but recent 
advances in materials and methods have significantly improved 
the ability to ablate lesion tissue accurately and safely while spar-
ing nearby brain tissue. Two series have had good results (albeit 
in small samples with short follow-up) for tumors that failed to 
respond to traditional radiotherapy and subsequently underwent 
LITT. The technology allows biopsy and subsequent laser abla-
tion from a small (approximately 4  mm) access port inserted 
in the operating room. Carpentier et al. described four patients 
with six tumors treated with LITT without complications; no 
tumors recurred within the 90-day follow-up (37). Hawasli and 
colleagues demonstrated similar results using LITT for various 
lesions, including five metastases (38). Two patients suffered tran-
sient neurological morbidity (one aphasia and one hemiparesis), 
and two had progression of CNS disease 2.2 and 3.5 months after 
LITT. Nevertheless, LITT has good prospects as a means to extend 
quantity and quality of life for patients with radiation-resistant 
brain metastases in eloquent or deep locations who are left with 
few options. Furthermore, LITT can ablate radiation treatment 
effect found on biopsy. Further study is warranted.
PeRSOnALiZeD MeTASTASiS 
TReATMenT
As our technological ability to successfully treat brain metastases 
has grown in recent decades, so too has our knowledge of the 
intricate biology of tumorigenesis. The CNS is different from 
other organs, as blood-borne metastatic cells must first over-
come the blood–brain barrier after escaping their primary site 
of origin. Once these cells pass this barrier, they must establish 
themselves in a biological niche with a milieu of cytosolic growth 
factors unlike those of their site of origin. Lastly, once the cells 
have grown into a macroscopic tumor, different metastatic brain 
tumors have variable responses to irradiation and chemotherapy 
due to genetic and epigenetic alterations and poor penetration of 
the blood–brain barrier by some targeted chemotherapies. Each 
stage offers the potential for personalized, targeted intervention 
or, at least, better prognostication based on molecular (vs. histo-
logical) disease stratification. Many surgical clinical trials have 
grouped all metastatic tumors when evaluating new treatment 
strategies, but these lesions clearly have numerous biological dif-
ferences despite their commonality as “brain metastases.”
Molecular initiation of Distal Metastases
The molecular pathophysiology of brain metastasis has been the 
focus of extensive research. The ability to predict, via primary 
tumor tissue, which cancer patients will suffer brain metastasis 
would facilitate prognostication and focus metastasis screening 
efforts. Numerous lung cancer researchers have attempted to 
TABLe 2 | examples of metastatic events, their molecular processes, and 
potential targeted chemotherapeutics.
Cellular event Pathway(s)  
implicated
Potential personalized 
treatments
Migration across BBB cathepsin S Inhibitors in development
miR-181C None to date
miR-105 None to date
Survival in CNS 
microenvironment
mTOR Everolimus, temsirolimus
CDK Palbociclib, others in 
development
VEGF Bevacizumab
EGFR Erlotinib
Establishment of 
radioresistance
Chk1 Inhibitors in development
c-Met Cabozantinib
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correlate single gene mutations and chromosomal translocations 
with the development of brain metastases. For example, Lee et al. 
found that chromosomal amplifications of regions 5q35, 10q23, 
and 17q23–24 were associated with early development of brain 
metastases within 3 months of initial tumor diagnosis (39). The 
exact mechanisms by which these amplifications lead to lung-to-
brain metastasis are not yet understood. Genes associated with 
the development of brain metastases in lung cancer include PLGF, 
VEGFR1, c-MET, and CXCR4, all of which are targets for further 
investigation (40–42). HER2-positivity predisposes patients with 
breast cancer to the development of brain metastases. This predis-
position to brain metastases is probably caused by a combination 
of increased general HER2-positive tumor aggressive behavior as 
well as HER2-specific neural tropism via downstream pathways, 
such as TGF-β (43–45). Lastly, the pathophysiology of metastasis 
is not limited to protein-coding genes. Long non-coding RNA 
MALAT1 is associated with numerous cancer types and aggres-
sive tumor behavior, despite a relatively poor understanding of 
the exact function of this highly preserved non-coding RNA. 
Regardless, high tumor levels of MALAT1 RNA are correlated with 
poor overall survival in patients with lung-to-brain metastasis, and 
MALAT1 promotes brain metastasis via the induction of epithelial 
to mesenchymal transitions (46). Further research is warranted on 
this long non-coding RNA, which represents an interesting non-
protein target for personalized lung metastasis therapy.
Breaching the Blood–Brain Barrier
Once individual tumor cells have hematologically spread to the 
cerebral microvasculature, they must exit into the perivascular 
space across the blood–brain barrier to propagate macroscopic 
tumors. Pharmacological blockade of this transgression is a highly 
appealing strategy to prevent the formation of brain metastases. 
Research on multiple tumor types has elucidated the mechanics 
of this process, although much work remains. An elegant murine 
model by Kienast and colleagues characterized the individual 
steps of metastasis formation as tumor cells reach the brain 
(47). First, individual tumor cells arrest in tiny vessel branches. 
Next, cells that go on to form macroscopic tumors transmigrate 
across the vasculature wall within 72 h after being lodged into 
the capillary. After transmigration, formation of a macroscopic 
tumor requires that tumor cells proliferate in direct contact with 
endothelial cells of the brain capillary akin to a pericyte. Cells 
that do not maintain proximity to the vessel wall regress. Lastly, 
vessel co-option and angiogenesis must allow for sufficient nutri-
ent delivery to propagate the macrometastasis (47). Each step is 
driven by complex molecular interactions between the tumor 
cell and its surroundings, and all these interactions are potential 
targets for more directed, individualized therapies. The process of 
cellular transmigration out of the capillary is regulated by com-
plex junctional adhesion molecules, and proteases that degrade 
these junctional adhesions are implicated in brain metastasis. 
For example, high levels of cathepsin S are negatively associated 
with overall brain-metastasis-free survival in patients with breast 
cancer (48). Depletion of cathepsin S in a murine model reduced 
in vivo experimental brain metastases, thus identifying another 
potential personalized target for those patients with high tumor 
cathepsin S expression (48). The degradation of the blood–brain 
barrier by tumor cells is regulated not only by protein-protein 
interactions but also by non-canonical means. Tominaga et  al. 
demonstrated that breast cancer cells release extracellular vesi-
cles, including microRNA such as miR-181C, which promotes 
the local destruction of the blood–brain barrier via actin fiber 
delocalization in a PDPK1-mediated fashion (49). Other exoso-
mal microRNAs, such as miR-105, have also been implicated in 
the loss of cell–cell adhesion at tight junctions (50). The blockade 
of microRNA signaling pathways is not yet clinically practical but 
may represent future targeted therapies.
Metastatic evolution
Once established within the brain parenchyma, metastatic tumor 
cells continue to evolve (Table 2). Excellent genomic studies have 
demonstrated that brain metastases harbor gene alterations dis-
tinct from the primary tumor. These alterations have widespread 
ramifications, especially for patients with inoperative brain 
metastases whose primary lesion is the only tissue available for 
molecular profiling for additional therapy selection. Brastianos 
et al. found that in 53% of tumors, clinically relevant alterations 
occurred in the brain metastasis but not in the primary tumor 
(51). Many of these mutations arose in the PI3K/AKT/mTOR, 
CDK, and HER2/EGFR pathways, all of which have inhibitors 
available for clinical use. In this same cohort, multiple distinct 
brain lesions were genetically homogeneous compared to the 
extracranial metastases (51). This genetic homogeneity has 
significant practical implications because personalized targeted 
therapies for multiple brain lesions are best chosen on the basis of 
molecular data from any single brain metastasis rather than from 
the more divergent primary tumor or extracranial metastatic dis-
ease. Similar results demonstrate significant genetic divergence 
between brain metastasis and primary tumor tissue, specifically 
for squamous cell lung cancer (52). Further DNA- and RNA-
based high-throughput sequencing comparing primary tissue 
and brain metastases will shed additional light on the metastatic 
process (and subsequent potential therapies) in coming years.
Targeted Drug Delivery
Personalization of metastatic cancer treatment aims to improve 
treatment by using select therapies chosen via molecular profiling 
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to benefit the patient while sparing the patient from biologically 
irrelevant therapies with potential toxicity. In brain metastases, 
this strategy is limited because of poor penetration of most 
novel chemotherapeutics across the blood–brain barrier. Earlier 
research has used mannitol as a non-specific agent for blood–
brain barrier permeation with limited success (53). Researchers 
have since demonstrated the ability to permeate the blood–brain 
barrier selectively in murine models at the site of metastases using 
intravenous tumor necrosis factor (54). Although in its infancy, 
MR-focused ultrasound combined with microbubbles represents 
another method of blood–brain barrier disruption but requires 
significant dedicated infrastructure (55). Many novel targeted 
delivery strategies are in development in multiple centers, making 
it likely that more options will become available in the future.
Advances in Radiotherapy
At times, the molecular biology of radiation resistance can be 
overcome, allowing for more effective delivery of radiotherapy. 
Xenograft brain metastasis in murine models have demonstrated 
improved survival and response to external beam radiation after 
inhibition of Chk1 (DNA damage checkpoint protein) and c-Met 
(receptor tyrosine kinase with downstream oncogenes) (56–59). 
Clinical trials are required to demonstrate a benefit in human 
patients.
SUMMARY AnD FUTURe DiReCTiOnS
Brain metastases represent a common source of morbidity 
and mortality for cancer patients. Current treatment paradigms 
include surgical resection, radiotherapy, and chemotherapy. 
Recent advances in intraoperative surgical technology (i.e., 
fluorescence, confocal microscopy, and brachytherapy) hold 
promise for improved outcomes for brain metastasis resec-
tion. The future of brain metastasis management is predicated 
on personalized therapy targeted to specific tumor molecular 
pathways, such as those involved in blood–brain barrier trans-
gression, cell–cell adhesion, and angiogenesis. Brain metastases 
are often biologically distinct lesions compared to the primary 
tumor. Personalized therapies should therefore be chosen on 
the basis of brain metastasis tissue whenever available. The 
multidisciplinary management of patients with brain metastases 
by neurosurgeons, medical oncologists, and radiation oncolo-
gists is essential as therapies become increasingly complex and 
individualized.
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